. Author manuscript; available in PMC: 2012 Jun 25.

Published in final edited form as: Cardiovasc Revasc Med. 2010 Oct 20;12(2):111–122. doi: 10.1016/j.carrev.2010.05.003

TABLE 2.

Serial MR measurements of global LV function and mass before and after delivery of the genes. Note that the genes were derived 5 weeks after infarction.

Groups	5 weeks after infarction		5 weeks after therapy

Parameters	pCK-LacZ	pCK-HGF	pCK-LacZ	pCK-HGF
EDV (ml/kg)	2.10±0.05	2.03±0.08	2.03±0.06	1.99±0.09
ESV (ml/kg)	1.31±0.06	1.27±0.05	1.28±0.05	1.10±0.05^*⁺
Stroke volume (ml)	36±2	33±2	40±1	47±2^*⁺
Ejection fraction (%)	38±2	38±1	37±1	43±1^*⁺
Cardiac output (L)	3.3±0.2	3.2±0.3	3.4±0.2	4.2±0.3
LV mass (g)	96±3	102±5	117±4	123±4
MR infarct scar (%LV)	12.4±1.1	11.3±2.0	12.7±0.2	6.7±1.3^**⁺⁺
TTC (%LV)			12.1±0.7	7.2±0.9^**⁺⁺

P<0.05

^**

P<0.01 compared to pCK-LacZ control animals at 5 weeks after treatment (unpaired t-test).

⁺

P<0.05

⁺⁺

P<0.01 compared to 5 weeks prior treatment (paired t-test)